STIM Neuronetics

Filed: 2 Jul 21, 4:46pm





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 30, 2021




(Exact name of registrant as specified in its charter)




Delaware 001-38546 33-1051425

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)


3222 Phoenixville Pike, Malvern, PA 19355
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code (610) 640-4202

(Former name or former address, if changed since last report.) Not applicable.



Securities registered pursuant to Section 12(b) of the Act:


Title of each class



Symbol (s)


Name on each exchange

on which registered

Common Stock ($0.01 par value) STIM The Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.



On June 30, 2021, the Compensation Committee of the Board of Directors of Neuronetics, Inc. (the “Company”) approved the extension of the reimbursement benefit for travel and relocation assistance for Stephen Furlong, the Company’s Chief Financial Officer, which was set to expire on July 22, 2021.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: July 2, 2021   By: 

/s/ W. Andrew Macan

   Name: W. Andrew Macan 

Senior Vice President, General Counsel, Chief

Compliance Officer and Corporate Secretary